WEKO3
アイテム
膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点
http://hdl.handle.net/10191/4513
http://hdl.handle.net/10191/45138bc1b44e-db85-44e6-b003-d2ccc43cd100
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
KJ00004300071.pdf (604.4 kB)
|
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2007-05-10 | |||||
| タイトル | ||||||
| タイトル | 膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点 | |||||
| タイトル | ||||||
| タイトル | 膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点 | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | 膵癌 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | gemcitabine | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | 無作為化比較試験 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | 術後補助療法 | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| その他のタイトル | ||||||
| その他のタイトル | Multi-institutional Randomized Control Trial on the Efficacy of Adjuvant Chemotherapy Using Gemcitabine : A Preliminary Study | |||||
| 著者 |
黒崎, 功
× 黒崎, 功× 二瓶, 幸栄× 横山, 直行× 畠山, 勝義× 土屋, 嘉昭× 清水, 武昭 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background: We evaluated gemcitabine as postoperative adjuvant chemotherapy for patients with resectable advanced pancreatic cancer. Study design: Multi-institutional randomized control trial for phase IE clinical study. Patients and Methods: Patients who underwent a curative surgery for the pancreatic cancer of Stage n, fll, and F a were enrolled in this study. The chemotherapy group has been received administration of biweekly 1000mg/m2 gemcitabine for 6 months after surgery, while the surgery-alone group has not been received any anticancer drug. The primary end-point was the disease-free survival, over-all survival and feasibility. Results: Twelve patients were enrolled in this trial from 7 institutions from November 2001 to August 2003. The chemotherapy was well tolerated with mild symptomatic and hematologic toxi-cities. The Grade 3 toxicity was observed only in two patients; one was nausea and vomiting requiring dripped infusion and the other was leucocytopenia. However, from the close micro-scopic examination, only 6 patients were eligible. Conclusions: Adjuvant systemic chemotherapy using gemcitabine was feasible with acceptable adverse effects. Further investigation for gemcitabine - based chemotherapy is warranted. | |||||
| 書誌情報 |
新潟医学会雑誌 en : 新潟医学会雑誌 巻 119, 号 2, p. 90-94, 発行日 2005-02 |
|||||
| 出版者 | ||||||
| 出版者 | 新潟医学会 | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 00290440 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AN00182415 | |||||
| 著者版フラグ | ||||||
| 値 | publisher | |||||
